Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study

INTRODUCTION AND AIMS: The DIPAK-1 Study investigates the reno- and hepatoprotective efficacy of the somatostatin analog lanreotide compared with standard care in patients with later stage autosomal dominant polycystic kidney disease (ADPKD). During this trial, we witnessed several episodes of hepat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lantinga, Marten A., D’Agnolo, Hedwig M. A., Casteleijn, Niek F., de Fijter, Johan W., Meijer, Esther, Messchendorp, Annemarie L., Peters, Dorien J. M., Salih, Mahdi, Spithoven, Edwin M., Soonawala, Darius, Visser, Folkert W., Wetzels, Jack F. M., Zietse, Robert, Drenth, Joost P. H., Gansevoort, Ron T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288423/
https://www.ncbi.nlm.nih.gov/pubmed/27995519
http://dx.doi.org/10.1007/s40264-016-0486-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288423/
https://www.ncbi.nlm.nih.gov/pubmed/27995519
http://dx.doi.org/10.1007/s40264-016-0486-x

Ejemplares similares